Related Experiment Videos

Temozolomide-related infections: review of the literature

M C Kizilarslanoglu1, S Aksoy, N O Yildirim

  • 1Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|October 19, 2011
PubMed

Insights

Temozolomide (TMZ) treatment can lead to serious opportunistic infections due to T-cell dysfunction. Close monitoring is crucial as these infections, including candidiasis and viral reactivation, carry a significant mortality risk.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Pharmacology

Background:

  • Temozolomide (TMZ) is an antineoplastic agent used for brain tumors and melanoma.
  • TMZ can cause lymphopenia and T-cell dysfunction, increasing infection risk.
  • Opportunistic infections associated with TMZ are not well-characterized.

Purpose of the Study:

  • To investigate and characterize opportunistic infections in patients treated with Temozolomide.
  • To analyze the types, frequency, and outcomes of these infections.

Main Methods:

  • A literature review was conducted using Medline to identify relevant English-language studies.
  • 36 previously reported cases of infection related to TMZ were analyzed.
  • Data on patient demographics, infection types, and outcomes were compiled.

Main Results:

  • The most common infections included mucocutaneous candidiasis (28.2%), herpes zoster (12.8%), and cytomegalovirus (CMV) (12.8%).
  • Other significant infections were herpes simplex virus (10.2%), Pneumocystis carinii pneumonia (PCP) (7.6%), and hepatitis B virus (HBV) (5.1%).
  • The mortality rate for reported outcomes was 28.5%, with one-third of severe infections resulting in death.

Conclusions:

  • Patients receiving Temozolomide are at an elevated risk for opportunistic viral and bacterial infections.
  • Close monitoring for opportunistic infections is essential in patients undergoing TMZ therapy.
  • Awareness of these risks can guide clinical management and improve patient outcomes.

Related Concept Videos

Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...